PMV Pharmaceuticals
Update in progressPMVP (NasdaqGS)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryBiotechnology
PMV Pharmaceuticals, Inc. is a precision oncology company focused on discovering and developing small molecule therapies for p53 mutations and other p53-related cancers in the United States. It is advancing rezatapopt, a selective structural corrector for p53 Y220C mutations, in Phase 2 trials for tumor-agnostic diseases. Formerly PJ Pharmaceuticals, the company renamed PMV in July 2013. It was incorporated in 2013 and is headquartered in Princeton, New Jersey.
Company score
- Sentiment
- 0.14
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.00
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 0.46
- Governance
- 0.24
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- 0.19
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- 0.17
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Sort by
Order by
Timeframe
No news articles are available for this company yet.
Unable to load company news.
Loading more news
You're all caught up!